Overview

• Celltrion has been named preferred bidder for an existing U.S. biopharmaceutical manufacturing facility to avoid a looming 25 percent reciprocal tariff on South Korean imports.
• The company is conducting due diligence on the site and aims to complete the acquisition by year-end.
• Celltrion plans an initial investment of 700 billion won with options to invest an additional 300 billion won for small-scale expansion or up to 700 billion won for a large-scale build-out.
• Acquiring an operational plant allows Celltrion to produce its therapies locally and shield U.S. shipments from tariff costs without constructing a new facility.
• The move aligns with Celltrion’s goal to expand its global biosimilar lineup to 22 products by 2030 and 41 by 2033.